{"groups":[{"description":"Participants in this dose-escalation cohort self-administered enasidenib mesylate orally at a dose of 100 mg once daily.","id":"FG000","title":"Enasidenib Mesylat 100mg"},{"description":"Participants in this dose-escalation cohort self-administered enasidenib mesylate orally at a dose of 200 mg once daily.","id":"FG001","title":"Enasidenib Mesylat 200mg"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"14"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"8"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"6"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}